• Cefixime Tablets
  • Jinying Capsule
  • Yuanqi Boneal Tincture
  • Cihang Capsule
  • Xuesaitong Dispersible Tablets

position:home >> Big Events


New Drug for Hepatitis B of Fangsheng Pharma gets the new drug certificate and drug registration certificate


According to the Drug Administration Law of the People's Republic of China, our production, Adefovir Dipivoxil Dispersible Tablets, meets the requirement of drug registration and gets its new drug certificate and drug registration certificate.

I New Drug Certificate
Drug Name: Adefovir Dipivoxil Dispersible Tablets
Certificate Number: Chinese Medicine Certificate H20150033
Main Ingredients: Adefovir Dipivoxil

II Drug Registration Certificate
Drug Name: Adefovir Dipivoxil Dispersible Tablets
Main Ingredients: Adefovir Dipivoxil
Dosage Form: Tablet
Specifications: 10 mg
Document Number: 2015S00515
Register Classification: Chemical medicine 3.1 type
Drug Approval Number: Chinese medicine certificate H20150051
Drug Approval Number Expiration Date: Until July 8th 2020
Adefovir Dipivoxil Dispersible Tablet is applicable in treatment of adult patients with chronic hepatitis B with the liver compensatory function including hepatitis B virus with replication evidence and associated with serum amino shift enzyme (ALT or AST) continues to rise or active lesions of liver tissue. At present, there are two kinds of forms, ordinary tablets and capsules. Dispersible tablets is approved for production only in Fangsheng Pharma of all the drug production enterprises in China, which is called exclusive formulations. The drug approval document is obtained to further and enrich the company's product range, optimizes the product structure.

Contact From

Fangsheng Company

No.789,Lusong Road

Yuelu District,Changsha,China

Business Consultation:+86-0731-88997188

Complaints Hotline:+86-0731-88908622